PSMA (prostrate-specific membrane antigen) is a protein that is highly expressed on most of the tumor cells in prostate cancer. It is also expressed on the (neo)vasculature that supplies blood to many other tumors. We have developed a site specific ADC which uses our proprietary drug payload and we are currently evaluating its efficacy and overall toxicity compared with conventional ADCs. Thus, our ADCs have the potential to demonstrate increased potency in cancer patients while decreasing the toxicity that is usually seen in other ADCs due to the heterogeneity of the random conjugation approach used to generate these molecules. We are developing the anti-PSMA ADC for indications in prostate cancer and glioblastoma multiforme.